Slingshot members are tracking this event:

European Medicines Agency Accepts Bristol-Myers Squibb's (BMY) Marketing Application for New Use of Opdivo in Locally Advanced Unresectable or Metastatic Urothelial Carcinoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Opdivo, Marketing Application, European Medicines Agency, Locally Advanced Unresectable, Metastatic Urothelial Carcinoma